89bio To Report Severe Hypertriglyceridemia Trial Data In Q2

89bio Inc. (ETNB) has a key clinical trial catalyst to watch in the coming months. The company's lead drug candidate is Pegozafermin, formerly BIO89-100, a long-acting engineered glycopegylated recombinant human fibroblast growth factor 21 (FGF21) analogue, being developed for severe hypertriglyceridemia and non-alcoholic steatohepatitis.

from RTT - Top Story https://ift.tt/LNt12Vv
via IFTTT